Profile data is unavailable for this security.
About the company
Hangzhou Biotest Biotech Co Ltd is a company mainly engaged in the research and development (R&D), production and sales of point-of-care testing (POCT) diagnostic reagents. The Company's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.
- Revenue in CNY (TTM)518.65m
- Net income in CNY104.29m
- Incorporated2008
- Employees629.00
- LocationHangzhou Biotest Biotech Co LtdNo. 27, Tuyi RoadCangqian Neighborhood, Yuhang DistrictHANGZHOU 311100ChinaCHN
- Phone+86 57 189058091
- Fax+86 57 189058091
- Websitehttp://www.biotests.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Hotgen Biotech Co Ltd | 520.50m | -67.64m | 2.80bn | 1.04k | -- | 0.8585 | -- | 5.38 | -0.7349 | -0.7349 | 5.74 | 35.25 | 0.1484 | 2.20 | 5.85 | 502,410.60 | -2.13 | 29.65 | -2.22 | 34.70 | 46.98 | 56.08 | -14.33 | 32.26 | 8.95 | -- | 0.0026 | 41.92 | -84.78 | 23.67 | -97.10 | -10.67 | 57.98 | -- |
| Chemclin Diagnostics Co Ltd | 443.86m | 139.29m | 2.93bn | 731.00 | 21.00 | 2.09 | -- | 6.60 | 0.3476 | 0.3476 | 1.11 | 3.49 | 0.2491 | 1.00 | 16.34 | 607,195.30 | 7.82 | 11.01 | 8.73 | 12.32 | 74.89 | 74.19 | 31.38 | 31.07 | 5.16 | -- | 0.1515 | 36.64 | -4.28 | 4.00 | -3.44 | -- | 44.10 | -- |
| Nanjing Vishee Medical Technology Co Ltd | 422.21m | 112.74m | 2.96bn | 700.00 | 26.16 | 1.84 | -- | 7.01 | 1.18 | 1.18 | 4.42 | 16.83 | 0.2401 | 3.12 | 12.37 | 603,153.40 | 6.41 | 10.27 | 6.92 | 11.43 | 70.21 | 73.26 | 26.70 | 33.99 | 8.31 | -- | 0.0003 | 47.57 | 43.72 | 17.34 | 45.22 | 16.55 | 26.69 | -- |
| Beijing Succeeder Technology Inc | 297.74m | 112.75m | 3.03bn | 296.00 | 26.95 | 1.85 | -- | 10.18 | 1.06 | 1.06 | 2.80 | 15.41 | 0.1766 | 2.51 | 8.66 | 1,005,870.00 | 6.69 | 7.77 | 7.02 | 8.25 | 60.39 | 61.03 | 37.85 | 38.34 | 14.78 | -- | 0.00004 | 22.22 | 20.40 | 6.60 | 12.29 | 15.57 | 99.03 | -- |
| Cowealth Medical China Co Ltd | 970.41m | 29.67m | 3.04bn | 240.00 | 102.39 | 2.60 | -- | 3.13 | 0.0745 | 0.0745 | 2.44 | 2.93 | 0.6435 | 3.90 | 1.25 | 4,043,355.00 | 2.01 | 5.80 | 2.59 | 8.09 | 19.62 | 20.74 | 3.13 | 6.14 | 3.65 | -- | 0.0829 | 23.89 | -14.62 | 3.85 | -42.96 | -6.75 | 32.85 | -- |
| Hangzhou Biotest Biotech Co Ltd | 518.65m | 104.29m | 3.21bn | 629.00 | 30.40 | 1.35 | -- | 6.19 | 0.9897 | 0.9897 | 4.94 | 22.27 | 0.204 | 2.61 | 6.85 | 824,563.60 | 4.01 | 29.45 | 4.23 | 33.30 | 52.42 | 56.83 | 19.64 | 41.59 | 12.53 | -- | 0.0003 | 29.32 | -76.75 | 19.65 | -86.22 | 41.33 | 34.82 | -- |
| Shanghai Kindly Enterprise Dev Gp Co Ltd | 2.28bn | 209.26m | 3.40bn | 4.23k | 16.06 | 1.36 | -- | 1.49 | 0.4796 | 0.4796 | 5.24 | 5.68 | 0.5585 | 3.89 | 2.41 | 540,095.70 | 5.79 | 8.09 | 9.27 | 16.09 | 30.45 | 36.01 | 10.37 | 12.53 | 1.25 | -- | 0.1931 | 26.55 | -21.36 | 11.08 | -25.92 | 9.44 | 4.85 | 1.30 |
| Shanghai General Hthy Info & Tech Co Ltd | 261.57m | 18.00m | 3.40bn | 355.00 | 188.93 | 3.18 | -- | 13.00 | 0.1324 | 0.1324 | 1.92 | 7.88 | 0.1908 | 1.16 | 0.5944 | 736,806.40 | 1.03 | 11.22 | 1.32 | 14.13 | 61.95 | 53.64 | 5.42 | 30.54 | 2.58 | -- | 0.1216 | 14.00 | -4.59 | 3.70 | -48.13 | -4.27 | 9.32 | -- |
| Shanghai ZJ Bio-Tech Co Ltd | 206.71m | -184.51m | 3.51bn | 305.00 | -- | 0.9299 | -- | 16.97 | -1.03 | -1.03 | 1.11 | 19.64 | 0.0507 | 0.1893 | 2.00 | 677,741.90 | -4.52 | 17.08 | -4.74 | 19.18 | 68.92 | 60.21 | -89.26 | 34.13 | 18.50 | -- | 0.0014 | 34.15 | -88.21 | 4.10 | -118.00 | -- | 35.93 | -- |
Data as of Sep 13 2024. Currency figures normalised to Hangzhou Biotest Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
10.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.94m | 7.41% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 328.55k | 0.83% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 261.44k | 0.66% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024 | 138.76k | 0.35% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024 | 112.83k | 0.28% |
| Broad Fund Management Co. Ltd.as of 30 Jun 2024 | 66.80k | 0.17% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 59.49k | 0.15% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 53.22k | 0.13% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 50.81k | 0.13% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 33.50k | 0.08% |
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
